This HTML5 document contains 176 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n11http://dx.doi.org/10.1016/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
phttp://www.wikidata.org/prop/
wikibasehttp://wikiba.se/ontology#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q101139018
rdf:type
wikibase:Item
schema:description
vetenskaplig artikel 2020年學術文章 artículo científico publicado en 2020 სამეცნიერო სტატია научна статия 2020年學術文章 wissenschaftlicher Artikel artykuł naukowy naučni članak επιστημονικό άρθρο 2020年の論文 articolo scientifico scientific article published on 29 October 2020 2020年學術文章 artikel ilmiah teaduslik artikkel article scientific наукова стаття, опублікована в жовтні 2020 2020年学术文章 artigo científico tudományos cikk videnskabelig artikel udgivet 29. oktober 2020 vitenskapelig artikkel bài báo khoa học article científic scientific article published on 29 October 2020 2020 nî lūn-bûn ২৯ অক্টোবর ২০২০-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ bilimsel makale 2020年学术文章 artikull shkencor vitskapeleg artikkel научная статья научни чланак 2020年学术文章 artigo científico мақолаи илмӣ scientific article published on 29 October 2020 wetenschappelijk artikel מאמר מדעי vědecký článek научни чланак 2020年學術文章 2020年学术文章 artigo científico مقالة علمية نشرت في 29 أكتوبر 2020 scienca artikolo 2020年學術文章 tieteellinen artikkeli vedecký článok 2020年学术文章 artikulong pang-agham articol științific artículu científicu บทความทางวิทยาศาสตร์ article scientifique 2020年学术文章 2020년 논문
p:P577
wds:Q101139018-DAD1D050-968F-4B15-AFA1-FDB978571E21
wdt:P577
2020-10-29T00:00:00Z
p:P2860
wds:Q101139018-F1CFF9E4-EFF8-4D6D-B09D-9B69994AE24D wds:Q101139018-EFCB14FB-65F4-4F18-B35A-B2C056E18A27 wds:Q101139018-FEDC25A2-5774-4B80-949E-8B98C46ADD79 wds:Q101139018-E401B74C-FB67-4EE9-9A4D-8AD8F8130605 wds:Q101139018-C8592B24-3CA9-4439-B986-C824E6BC11F4 wds:Q101139018-BF5C039F-1726-413F-8DE8-98512B28434C wds:Q101139018-D1A375F6-FD73-4263-883E-13FDE5354CF8 wds:Q101139018-CE5FB6DE-7F4F-460D-9E19-EFBB04332B5B wds:Q101139018-BA80C58E-52A8-4206-AAE6-8A3F1D697793 wds:Q101139018-B2344E41-954B-4EEC-BF50-F5E3E6F47EF1 wds:Q101139018-BCC470AC-6413-44AE-8402-E506E376ECC2 wds:Q101139018-BC6FBA58-609F-4220-B3DF-69B705EC388D wds:Q101139018-A8F0F684-B1D3-4097-84A1-CB8F6D677075 wds:Q101139018-AE0F41BE-1B2D-4CAC-84FE-91765450498A wds:Q101139018-86EE01C8-0EE0-4972-B681-490CF72594FA wds:Q101139018-813FB905-29D8-45D3-9F15-083B11BD61C7 wds:Q101139018-999CD567-AB74-4833-B0CC-BE0A0BBF7B0D wds:Q101139018-9170B941-A8FB-4093-8450-944249DED6CB wds:Q101139018-7AD0F4D4-CEC7-4666-B13B-3D40350FA8B3 wds:Q101139018-75C32B16-59C4-4685-B38A-18FEFB1E019D wds:Q101139018-7D9F6DCB-46D0-4D8C-961A-743EAC8441A8 wds:Q101139018-7B29A2FE-CCFD-4A30-BE2E-F5E034764E66 wds:Q101139018-659EB65E-196A-44E8-A2B7-82B62946CE44 wds:Q101139018-61B2FB2E-2D95-4B34-B675-17E2AB1F413D wds:Q101139018-717B29E2-3980-48E4-ADDB-9F03310FBF58 wds:Q101139018-5689B555-2E4C-4007-93A9-387628A50933 wds:Q101139018-482FC351-23C0-4C6D-AE6C-02756E44BAAD wds:Q101139018-5882CFDA-2463-4AC1-A13C-9AED292EBDB5 wds:Q101139018-56F986FF-C65C-4F37-B289-D3ECEF6D91C4 wds:Q101139018-38E2E2DC-1A5E-404B-846A-71487F9F4FBC wds:Q101139018-370D8C4D-5340-4C9E-863C-CA41C65B23C1 wds:Q101139018-45216D06-C0A3-4282-B2C9-CE34727C8D1E wds:Q101139018-3D0AB911-FED0-464B-B182-380FAD3F5A91 wds:Q101139018-28277963-3D31-4FA9-A8A2-5A4A9B5F1273 wds:Q101139018-2D086887-741C-48B0-A35D-BB1528922C61 wds:Q101139018-17A3907E-1848-44FD-B32D-1F87E264DE67 wds:Q101139018-13FC6109-D5AF-443A-B536-28F1AD32A184 wds:Q101139018-1AF71789-8493-48EC-AF7F-61169DA842FA wds:Q101139018-17BD9DA9-6474-43B8-A0E0-1EE4FDF28576 wds:Q101139018-107B1D23-5008-4167-A668-F376FA092A5A wds:Q101139018-12E270C6-F0CB-4A29-BAB4-92CF27747382 wds:Q101139018-1239DF5F-3CDF-4C1F-9B8B-1C9F3BC6BF59 wds:Q101139018-0FB351D0-9D04-4583-BDA3-2D92DD13BF72
wdt:P2860
wd:Q97549518 wd:Q94656992 wd:Q38642477 wd:Q89794413 wd:Q35202343 wd:Q67201061 wd:Q39027800 wd:Q36651344 wd:Q57296843 wd:Q96225092 wd:Q40182586 wd:Q95841945 wd:Q88885438 wd:Q90387771 wd:Q34956211 wd:Q92129220 wd:Q37117624 wd:Q29303108 wd:Q92405218 wd:Q98293357 wd:Q46438521 wd:Q29617588 wd:Q52685045 wd:Q91763444 wd:Q92123956 wd:Q47332598 wd:Q91381462 wd:Q96307980 wd:Q57059973 wd:Q39798588 wd:Q37058104 wd:Q90018625 wd:Q91942062 wd:Q91396441 wd:Q92000371 wd:Q48792987 wd:Q92039571 wd:Q33406742 wd:Q50026906 wd:Q90286096 wd:Q96693172 wd:Q90009464 wd:Q91088002
p:P2093
wds:Q101139018-2085A131-1BCF-4C11-A2B4-B9FC99EA586D wds:Q101139018-AB4A8002-B9EB-4FAB-A557-0DB24F642E2B wds:Q101139018-A2228D69-0D00-4D52-9BD4-1D016203DC9E
wdt:P2093
Marcela V Maus Matthew J Frigault Mark B Leick
rdfs:label
Clinical Perspective: Treatment of Aggressive B-cell Lymphomas with FDA approved CAR-T cell therapies Clinical Perspective: Treatment of Aggressive B-cell Lymphomas with FDA approved CAR-T cell therapies Clinical Perspective: Treatment of Aggressive B-cell Lymphomas with FDA approved CAR-T cell therapies
skos:prefLabel
Clinical Perspective: Treatment of Aggressive B-cell Lymphomas with FDA approved CAR-T cell therapies Clinical Perspective: Treatment of Aggressive B-cell Lymphomas with FDA approved CAR-T cell therapies Clinical Perspective: Treatment of Aggressive B-cell Lymphomas with FDA approved CAR-T cell therapies
schema:name
Clinical Perspective: Treatment of Aggressive B-cell Lymphomas with FDA approved CAR-T cell therapies Clinical Perspective: Treatment of Aggressive B-cell Lymphomas with FDA approved CAR-T cell therapies Clinical Perspective: Treatment of Aggressive B-cell Lymphomas with FDA approved CAR-T cell therapies
p:P1476
wds:Q101139018-E24EA624-A6B6-43B7-93FF-8C5052EEE7E8
wdt:P1476
Clinical Perspective: Treatment of Aggressive B-cell Lymphomas with FDA approved CAR-T cell therapies
p:P31
wds:Q101139018-107E7119-7B00-4BCE-A7A8-FEB787FDCB45
wdt:P31
wd:Q13442814
p:P698
wds:Q101139018-0739D508-8C71-4233-80CD-FD52A2FFAA19
wdtn:P698
n12:33130313
wdt:P698
33130313
p:P1433
wds:Q101139018-6FE2890B-4C3B-4DA7-AF85-7E3822489996
wdt:P1433
wd:Q15762400
p:P356
wds:Q101139018-2DF3C866-8D84-4B67-A779-F35B7E55726B
wdtn:P356
n11:J.YMTHE.2020.10.022
wdt:P356
10.1016/J.YMTHE.2020.10.022
p:P932
wds:Q101139018-E38A7F28-03CA-4646-B9D5-FA852D038475
wdt:P932
7854294